Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool by Curtius, K, Kabir, M, Al Bakir, I, Johnson, M, East, JE

Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. by Hale, G, Rebello, P, Al Bakir, I, Bolam, E, Wiczling, P, Jusko, W, Vandemeulebroucke, E, Keymeulen, B, Mathieu, C, Ziegler, A, Chatenoud, L, Waldmann, H

Quantifying evolution of early dysplastic lesions in ulcerative colitis predicts future colorectal cancer risk by Curtius, K, Al Bakir, I, Baker, A, Clarke, T, Nasreddin, N, Kopczynska, M, Agnew, M, Smith, K, Moorghen, M, Rodriguez-Justo, M, Jansen, M, East, J, Wang, L, Hart, A, Graham, T

Evolutionary history of human colitis-associated colorectal cancer by Baker, A, Cross, W, Curtius, K, Al-Bakir, I, Choi, C, Davis, H, Biswas, S, Martinez, P, Williams, M, Lindsay, J, Feakins, R, Vega, R, Hayes, S, Tomlinson, I, McDonald, S, Moorghen, M, Silver, A, East, J, Wright, N, Wang, L, Rodriguez-Justo, M, Jansen, M, Hart, A, Leedham, S, Graham, T